The German start-up receives capital in a Series B round led by Gimv and EQT Life Sciences and prepares for the second phase of clinical trials
Click here to read previous Newsletters
Subscribe to the newsletter
yes
en
* I agree that my personal data will be used in accordance with the Privacy and Cookie Policy.
* I authorize the processing of my personal data to be updated on new arrivals and for direct marketing purposes related to the services offered.